SAN DIEGO, July 23, 2020 – MetVital, Inc., a privately held biopharmaceutical company developing small molecule modulators of altered glutamate metabolism for the treatment of diseases with significant unmet medical need and commercial potential, today announces that the National Institute of Health, National Institute of Neurological Disorders and Stroke has […]
Uncategorized
2 posts
SAN DIEGO, July 1, 2020 — MetVital, Inc., a privately held biopharmaceutical company developing small molecule modulators of altered glutamate metabolism for the treatment of diseases with significant unmet medical need and commercial potential, today announces that the U.S. Food and Drug Administration (FDA) has notified MetVital that its lead drug candidate, […]